Clinical trials: Hepatocellular Carcinoma Resectable
Hepatocellular Carcinoma Non-resectable, Effect of Drug
Predicting Response to Systemic Therapies for Hepatocellular Carcinoma(HCC)
As the most common type of primary liver cancer, hepatocellular carcinoma (HCC) has become a big challenge all over the world. Most patients are not available to curative resection when first diagnosed.
- Trial name
- NCT05543304
- Testing
- radiological evaluation
- Where
- China
- Volunteers
- 200 people
- Sponsor
- First Affiliated Hospital of Wenzhou Medical University
Hepatocellular Carcinoma, Hepatic Chemotherapy
TACE Combined Surgery for the Resectable Huge HCC
Huge hepatocellular carcinoma (HCC) is defined as a tumor with a maximum diameter greater than 10 cm. With advancements in surgical techniques, hepatectomy can be performed safely in some patients with huge HCC without vascular…
- Conditions
- Hepatocellular Carcinoma, Hepatic Chemotherapy, Liver Cancer, Surgery
- Trial name
- NCT06898398
- Testing
- TACE, Surgery
- Where
- China
- Volunteers
- 326 people
- Sponsor
- Sun Yat-sen University
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
Stereotactic Body Radiation Therapy in Liver Cancer That Cannot be Removed by Surgery or Transplant
RATIONALE: Radiation therapy uses high energy x-rays to kill tumor cells. Stereotactic body radiation therapy may be able to send x-rays directly to the tumor and cause less damage to normal tissue in patients with liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT01194206
- Testing
- stereotactic body radiation therapy
- Sponsor
- Case Comprehensive Cancer Center
Hepatocellular Carcinoma, Liver Cancer
Microwave Ablation of Resectable Liver Tumors
The purpose of this protocol is to pathologically evaluate the destruction by microwave ablation of primary and metastatic liver tumors.
- Trial name
- NCT00892255
- Testing
- Microwave Ablation
- Where
- United States
- Sponsor
- St. Joseph Hospital of Orange
Hepatocellular Carcinoma
Sintilimab Combined With Bevacizumab Biosimilar for Potentially Resectable Intermediate HCC
This is a Phase Ib study to evaluate the safety and efficacy of sintilimab combined with bevacizumab biosimilar in patients with potentially resectable intermediate hepatocellular carcinoma (HCC).
- Trial name
- NCT04843943
- Testing
- Sintilimab, Bevacizumab Biosimilar
- Volunteers
- 30 people
- Sponsor
- Fudan University
Resectable Hepatocellular Carcinoma
Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma
This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.
- Trial name
- NCT04834986
- Testing
- Tislelizumab combined with Lenvatinib
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8
Atezolizumab and Bevacizumab Before Surgery for the Treatment of Resectable Liver Cancer
This phase II trial studies the effect of atezolizumab and bevacizumab before surgery in treating patients with liver cancer that can be removed by surgery (resectable).
- Conditions
- Resectable Hepatocellular Carcinoma, Stage I Hepatocellular Carcinoma AJCC v8, Stage IA Hepatocellular Carcinoma AJCC v8, Stage IB Hepatocellular Carcinoma AJCC v8
- Trial name
- NCT04721132
- Testing
- Atezolizumab, Bevacizumab, Therapeutic Conventional Surgery
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- M.D. Anderson Cancer Center
Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma
Trametinib or Combination Chemotherapy in Treating Patients With Refractory or Advanced Biliary or Gallbladder Cancer or That Cannot Be Removed by Surgery
This randomized phase II trial studies how well trametinib or combination chemotherapy works in treating patients with refractory or advanced biliary or gallbladder cancer or that cannot be removed by surgery.
- Conditions
- Adult Cholangiocarcinoma, Advanced Adult Hepatocellular Carcinoma, BCLC Stage C Adult Hepatocellular Carcinoma, BCLC Stage D Adult Hepatocellular Carcinoma
- Trial name
- S1310 (NCT02042443)
- Testing
- Capecitabine, Fluorouracil, Laboratory Biomarker Analysis
- Where
- 295 sites in United States
- Volunteers
- 53 people
- Sponsor
- National Cancer Institute (NCI)
Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma
18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant
This clinical trial studies fluorine F 18 L-glutamate derivative BAY94-9392 (18F-FSPG) positron emission tomography (PET) in imaging patients with liver cancer before undergoing surgery or transplant.
- Conditions
- Adult Hepatocellular Carcinoma, Resectable Hepatocellular Carcinoma, Cholangiocarcinoma, Benign Liver Tumor
- Trial name
- NCT02379377
- Testing
- Fluorine F 18 L-glutamate Derivative 18F-FSPG, Carbon C 11 Acetate, Positron Emission Tomography
- Where
- United States
- Volunteers
- 110 people
- Sponsor
- M.D. Anderson Cancer Center
Potentially Resection, Hepatocellular Carcinoma
TACE-HAIC vs. HAIC for Potentially Resectable HCC
Hepatocellular carcinoma (HCC) is one of the most commonly malignant tumors around the world. Hepatic resection or liver transplantation is the radical method to cure the disease.
- Trial name
- NCT03591705
- Testing
- TACE-HAIC, HAIC
- Where
- China
- Volunteers
- 240 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma
HR Combined With FOLFOX4 for HCC With PVTT
Hepatocellular carcinoma (HCC) is the sixth most common cancer and the third most frequent cause of cancer death worldwide. Hepatic resection (HR) is the conventional ''curative'' treatment for HCC.
- Trial name
- NCT02452853
- Testing
- HR, FOLFOX4
- Volunteers
- 51 people
- Sponsor
- Sun Yat-sen University
Hepatocellular Carcinoma Non-resectable, Stereotactic Body Radiotherapy
Plasma Biomarker in Predicting Response and Toxicity in HCC Patients Treated With Checkpoint Inhibitors With or Without SBRT
This is a prospective study to investigate the biomarkers in predicting treatment outcome and toxicity in hepatocellular carcinoma (HCC) patients receiving immune checkpoint inhibitors with or without stereotactic body…
- Trial name
- NCT06408753
- Testing
- sterotatic body radiotherapy
- Where
- Hong Kong
- Volunteers
- 50 people
- Sponsor
- The University of Hong Kong
Hepatocellular Carcinoma Non-resectable
Lenvatinib Plus I-125 Seed Brachytherapy vs. Lenvatinib for TACE-refractory HCC
This study is conducted to evaluate the efficacy and safety of lenvatinib plus iodine-125 seed brachytherapy (Len-I) compared with lenvatinib (Len) alone for patients with hepatocellular carcinoma (HCC) refractory to…
- Trial name
- NCT05608213
- Testing
- Lenvatinib Plus I-125 Seed Brachytherapy, Lenvatinib
- Where
- China
- Volunteers
- 187 people
- Sponsor
- Second Affiliated Hospital of Guangzhou Medical University
Hepatocellular Carcinoma (HCC)
Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC
Lenvatinib is the standard of care for patients with advanced hepatocellular carcinoma (HCC). The aim of the single-arm, open-label, phase II clinical trial is to assess efficacy and safety of lenvatinib as a preoperative…
- Trial name
- NCT04241523
- Testing
- Lenvatinib 4 mg Oral
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- Shanghai Zhongshan Hospital
Locally Advanced Hepatocellular Carcinoma
Feasibility and Efficacy of Neoadjuvant Cabozantinib Plus Nivolumab (CaboNivo) Followed by Definitive Resection for Patients With Locally Advanced Hepatocellular Carcinoma (HCC)
The proposed study is an open-label, single institution, single arm phase 1b study of neoadjuvant cabozantinib plus nivolumab in patients with locally advanced HCC.
- Trial name
- NCT03299946
- Testing
- Cabozantinib, Nivolumab
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hepatocellular Carcinoma Non-resectable
Evaluate the Treatment With Sintilimab Injection Plus Endostar in Hepatocellular Carcinoma
It is a a single arm, observational clinical trial to evaluate the efficacy and safety of combination treatment with sintilimab injection plus endostar in untreated locally advanced or metastatic hepatocellular carcinoma.
- Trial name
- NCT03881501
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Huazhong University of Science and Technology
Hepatocellular Carcinoma Non-resectable
mFOLFOX7 Plus Camrelizumab and Apatinib in BCLC Stage A/B Hepatocellular Carcinoma Patients Beyond Milan Criteria
This study was designed to evaluate the effectiveness and safety of mFOLFOX7（Oxaliplatin,Calcium Levofolinate,Fluorouracil） combined with Apatinib and Camrelizumab for Hepatocellular Carcinoma.
- Trial name
- NCT06607107
- Testing
- mFOLFOX7 combined with Camrelizumab and apatinib
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Hepatocellular Carcinoma
Toripalimab in Combination With Lenvatinib and TACE for Conversion Therapy in Patients With Potentially Resectable HCC
Study introduction: this is a multicenter, randomized controlled study of patients with histopathologically confirmed hepatocellular carcinoma (HCC) who have not previously received systematic treatment for HCC, all the patients…
- Trial name
- NCT05056337
- Testing
- Lenvatinib 4 MG Oral Capsule [Lenvima], Toripalimab, TACE
- Where
- China
- Volunteers
- 220 people
- Sponsor
- Shanghai Zhongshan Hospital
Hepatocellular Carcinoma, Immunotherapy
Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma
Hepatocellular carcinoma (HCC) is the most common primary liver cancer. Hepatectomy is a curable and effective method. However, the recurrence rate is as high as 50%~70% in 5 years after surgery.
- Conditions
- Hepatocellular Carcinoma, Immunotherapy, Molecular Targeted Therapy
- Trial name
- NCT04521153
- Testing
- Camrelizumab, Apatinib Mesylate, Radical surgery
- Where
- China
- Volunteers
- 294 people
- Sponsor
- Shanghai Zhongshan Hospital
Potentially Resectable Hepatocellular Carcinoma
A Study of HAIC Combined With Lenvatinib and Envolizumab in Potentially Resectable Hepatocellular Carcinoma
This is a single term, open label, single Center, Phase II Trial. The study is to explore the efficacy and safety of FOLFOX-HAIC combined with Lenvatinib and Envolizumab in the treatment of patients with potentially resectable…
- Trial name
- NCT06143579
- Testing
- FOLFOX-HAIC+Lenvatinib+Envolizumab
- Volunteers
- 48 people
- Sponsor
- Sun Yat-sen University